{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:39:11Z","timestamp":1792787951933,"version":"4.5.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,3]],"date-time":"2025-03-03T00:00:00Z","timestamp":1740960000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,3,3]],"date-time":"2025-03-03T00:00:00Z","timestamp":1740960000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"the Chongqing Key Programs of Science and Health Cooperation","award":["2022ZDXM013"],"award-info":[{"award-number":["2022ZDXM013"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Urol"],"DOI":"10.1186\/s12894-025-01719-5","type":"journal-article","created":{"date-parts":[[2025,3,3]],"date-time":"2025-03-03T04:26:00Z","timestamp":1740975960000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Optimal PSA density threshold for prostate biopsy in benign prostatic obstruction patients with elevated PSA levels but negative MRI findings"],"prefix":"10.1186","volume":"25","author":[{"given":"Yiji","family":"Peng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengcheng","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fuhan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhipeng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiong","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4410-128X","authenticated-orcid":false,"given":"Wenhao","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,3]]},"reference":[{"issue":"3","key":"1719_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209\u201349.","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"1719_CR2","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.eururo.2020.09.042","volume":"79","author":"N Mottet","year":"2021","unstructured":"Mottet N, van den Bergh RCN, Briers E, Van den Broeck T, Cumberbatch MG, De Santis M, et al. EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate Cancer-2020 update. Part 1: screening, diagnosis, and local treatment with curative intent. Eur Urol. 2021;79(2):243\u201362.","journal-title":"Eur Urol"},{"issue":"1","key":"1719_CR3","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1080\/21681805.2018.1551243","volume":"53","author":"L Regis","year":"2019","unstructured":"Regis L, Celma A, Planas J, Lopez R, Roche S, Lorente D, et al. The role of negative magnetic resonance imaging: can we safely avoid biopsy in P.I.-R.A.D.S. 2 as in P.I.-R.A.D.S. 1? Scand J Urol. 2019;53(1):21\u20135.","journal-title":"Scand J Urol"},{"issue":"2","key":"1719_CR4","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/j.euf.2022.10.002","volume":"9","author":"F Pellegrino","year":"2023","unstructured":"Pellegrino F, Tin AL, Martini A, Vertosick EA, Porwal SP, Stabile A, et al. Prostate-specific antigen density cutoff of 0.15 Ng\/ml\/cc to propose prostate biopsies to patients with negative magnetic resonance imaging: efficient threshold or legacy of the past?? Eur Urol Focus. 2023;9(2):291\u20137.","journal-title":"Eur Urol Focus"},{"issue":"5","key":"1719_CR5","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1016\/j.euo.2019.08.015","volume":"3","author":"UG Falagario","year":"2020","unstructured":"Falagario UG, Martini A, Wajswol E, Treacy PJ, Ratnani P, Jambor I, et al. Avoiding unnecessary magnetic resonance imaging (MRI) and biopsies: negative and positive predictive value of MRI according to Prostate-specific antigen density, 4Kscore and risk calculators. Eur Urol Oncol. 2020;3(5):700\u20134.","journal-title":"Eur Urol Oncol"},{"issue":"5","key":"1719_CR6","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1111\/bju.13619","volume":"119","author":"NL Hansen","year":"2017","unstructured":"Hansen NL, Barrett T, Koo B, Doble A, Gnanapragasam V, Warren A, et al. The influence of prostate-specific antigen density on positive and negative predictive values of multiparametric magnetic resonance imaging to detect Gleason score 7\u201310 prostate cancer in a repeat biopsy setting. BJU Int. 2017;119(5):724\u201330.","journal-title":"BJU Int"},{"issue":"6","key":"1719_CR7","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1016\/j.eururo.2013.05.049","volume":"64","author":"S Loeb","year":"2013","unstructured":"Loeb S, Vellekoop A, Ahmed HU, Catto J, Emberton M, Nam R, et al. Systematic review of complications of prostate biopsy. Eur Urol. 2013;64(6):876\u201392.","journal-title":"Eur Urol"},{"issue":"13","key":"1719_CR8","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1056\/NEJMoa0908127","volume":"362","author":"GL Andriole","year":"2010","unstructured":"Andriole GL, Bostwick DG, Brawley OW, Gomella LG, Marberger M, Montorsi F, et al. Effect of dutasteride on the risk of prostate cancer. N Engl J Med. 2010;362(13):1192\u2013202.","journal-title":"N Engl J Med"},{"issue":"3","key":"1719_CR9","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1016\/j.eururo.2020.03.048","volume":"78","author":"NJ Sathianathen","year":"2020","unstructured":"Sathianathen NJ, Omer A, Harriss E, Davies L, Kasivisvanathan V, Punwani S, et al. Negative predictive value of multiparametric magnetic resonance imaging in the detection of clinically significant prostate Cancer in the prostate imaging reporting and data system era: A systematic review and Meta-analysis. Eur Urol. 2020;78(3):402\u201314.","journal-title":"Eur Urol"},{"issue":"4","key":"1719_CR10","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1038\/s41585-022-00678-y","volume":"20","author":"MS Lee","year":"2023","unstructured":"Lee MS, Assmus MA, Guo J, Siddiqui MR, Ross AE, Krambeck AE. Relationships between holmium laser enucleation of the prostate and prostate cancer. Nat Rev Urol. 2023;20(4):226\u201340.","journal-title":"Nat Rev Urol"},{"key":"1719_CR11","doi-asserted-by":"crossref","unstructured":"Capitanio U, Autorino R, Bandini M, Briganti A, Cheng L, Cooperberg MR et al. Incidental prostate Cancer (cT1a-cT1b) is a relevant clinical and research entity and should be fully discussed in the international prostate Cancer guidelines. Eur Urol Oncol. 2021.","DOI":"10.1016\/j.euo.2021.03.005"},{"issue":"11","key":"1719_CR12","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.1007\/s00345-017-2048-y","volume":"35","author":"A Herlemann","year":"2017","unstructured":"Herlemann A, Wegner K, Roosen A, Buchner A, Weinhold P, Bachmann A, et al. Finding the needle in a haystack: oncologic evaluation of patients treated for LUTS with holmium laser enucleation of the prostate (HoLEP) versus transurethral resection of the prostate (TURP). World J Urol. 2017;35(11):1777\u201382.","journal-title":"World J Urol"},{"issue":"1","key":"1719_CR13","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1089\/end.2014.0359","volume":"29","author":"N Bhojani","year":"2015","unstructured":"Bhojani N, Boris RS, Monn MF, Mandeville JA, Lingeman JE. Coexisting prostate cancer found at the time of holmium laser enucleation of the prostate for benign prostatic hyperplasia: predicting its presence and grade in analyzed tissue. J Endourol. 2015;29(1):41\u20136.","journal-title":"J Endourol"},{"issue":"6","key":"1719_CR14","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1007\/s10147-022-02156-2","volume":"27","author":"C Klein","year":"2022","unstructured":"Klein C, Marquette T, Capon G, Yacoub M, Alezra E, Bernhard JC, et al. Incidental prostate cancer after holmium laser enucleation of the prostate: incidence and predictive factors for clinical progression. Int J Clin Oncol. 2022;27(6):1077\u201383.","journal-title":"Int J Clin Oncol"},{"issue":"3","key":"1719_CR15","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1007\/s00345-014-1310-9","volume":"33","author":"S Otsubo","year":"2015","unstructured":"Otsubo S, Yokomizo A, Mochida O, Shiota M, Tatsugami K, Inokuchi J, et al. Significance of prostate-specific antigen-related factors in incidental prostate cancer treated by holmium laser enucleation of the prostate. World J Urol. 2015;33(3):329\u201333.","journal-title":"World J Urol"},{"issue":"3","key":"1719_CR16","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1016\/j.urology.2015.06.002","volume":"86","author":"MA Elkoushy","year":"2015","unstructured":"Elkoushy MA, Elshal AM, Elhilali MM. Incidental prostate Cancer diagnosis during holmium laser enucleation: assessment of predictors, survival, and disease progression. Urology. 2015;86(3):552\u20137.","journal-title":"Urology"},{"key":"1719_CR17","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.urology.2018.07.028","volume":"122","author":"P Capogrosso","year":"2018","unstructured":"Capogrosso P, Capitanio U, Vertosick EA, Ventimiglia E, Chierigo F, Oreggia D, et al. Temporal trend in incidental prostate Cancer detection at surgery for benign prostatic hyperplasia. Urology. 2018;122:152\u20137.","journal-title":"Urology"},{"key":"1719_CR18","doi-asserted-by":"publisher","first-page":"633196","DOI":"10.3389\/fsurg.2021.633196","volume":"8","author":"M Wenzel","year":"2021","unstructured":"Wenzel M, Welte MN, Grossmann L, Preisser F, Theissen LH, Humke C, et al. Multiparametric MRI May help to identify patients with prostate Cancer in a contemporary cohort of patients with clinical bladder outlet obstruction scheduled for holmium laser enucleation of the prostate (HoLEP). Front Surg. 2021;8:633196.","journal-title":"Front Surg"},{"issue":"11","key":"1719_CR19","doi-asserted-by":"publisher","first-page":"2079","DOI":"10.1007\/s11255-014-0777-z","volume":"46","author":"M Kim","year":"2014","unstructured":"Kim M, Song SH, Ku JH, Oh SJ, Paick JS. Prostate cancer detected after holmium laser enucleation of prostate (HoLEP): significance of transrectal ultrasonography. Int Urol Nephrol. 2014;46(11):2079\u201385.","journal-title":"Int Urol Nephrol"},{"issue":"15","key":"1719_CR20","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1056\/NEJMcp2209151","volume":"388","author":"PF Pinsky","year":"2023","unstructured":"Pinsky PF, Parnes H. Screening for prostate Cancer. N Engl J Med. 2023;388(15):1405\u201314.","journal-title":"N Engl J Med"},{"issue":"4","key":"1719_CR21","first-page":"Cd012663","volume":"4","author":"FH Drost","year":"2019","unstructured":"Drost FH, Osses DF, Nieboer D, Steyerberg EW, Bangma CH, Roobol MJ, et al. Prostate MRI, with or without MRI-targeted biopsy, and systematic biopsy for detecting prostate cancer. Cochrane Database Syst Rev. 2019;4(4):Cd012663.","journal-title":"Cochrane Database Syst Rev"},{"issue":"6","key":"1719_CR22","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1016\/j.clgc.2023.06.007","volume":"21","author":"P Pepe","year":"2023","unstructured":"Pepe P, Pennisi M. Targeted biopsy in men high risk for prostate cancer: (68)Ga-PSMA PET\/CT versus MpMRI. Clin Genitourin Cancer. 2023;21(6):639\u201342.","journal-title":"Clin Genitourin Cancer"},{"issue":"4","key":"1719_CR23","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1038\/pcan.2010.29","volume":"13","author":"P Pepe","year":"2010","unstructured":"Pepe P, Aragona F. Incidence of insignificant prostate cancer using free\/total PSA: results of a case-finding protocol on 14,453 patients. Prostate Cancer Prostatic Dis. 2010;13(4):316\u20139.","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"4","key":"1719_CR24","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1590\/S1677-55382012000400008","volume":"38","author":"P Pepe","year":"2012","unstructured":"Pepe P, Fraggetta F, Galia A, Skonieczny G, Aragona F. PCA3 score and prostate cancer diagnosis at repeated saturation biopsy. Which cut-off: 20 or 35? Int Braz J Urol. 2012;38(4):489\u201395.","journal-title":"Int Braz J Urol"},{"issue":"1","key":"1719_CR25","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1097\/JU.0000000000003491","volume":"210","author":"JT Wei","year":"2023","unstructured":"Wei JT, Barocas D, Carlsson S, Coakley F, Eggener S, Etzioni R, et al. Early detection of prostate cancer: AUA\/SUO guideline part I: prostate Cancer screening. J Urol. 2023;210(1):46\u201353.","journal-title":"J Urol"},{"issue":"2","key":"1719_CR26","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1111\/bju.13465","volume":"119","author":"S Washino","year":"2017","unstructured":"Washino S, Okochi T, Saito K, Konishi T, Hirai M, Kobayashi Y, et al. Combination of prostate imaging reporting and data system (PI-RADS) score and prostate-specific antigen (PSA) density predicts biopsy outcome in prostate biopsy Na\u00efve patients. BJU Int. 2017;119(2):225\u201333.","journal-title":"BJU Int"},{"issue":"3","key":"1719_CR27","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.euo.2018.09.001","volume":"2","author":"L Boesen","year":"2019","unstructured":"Boesen L, N\u00f8rgaard N, L\u00f8gager V, Balslev I, Bisbjerg R, Thestrup KC, et al. Prebiopsy biparametric magnetic resonance imaging combined with prostate-specific antigen density in detecting and ruling out Gleason 7\u201310 prostate Cancer in Biopsy-na\u00efve men. Eur Urol Oncol. 2019;2(3):311\u20139.","journal-title":"Eur Urol Oncol"},{"issue":"1","key":"1719_CR28","doi-asserted-by":"publisher","first-page":"132","DOI":"10.21037\/tau.2017.12.29","volume":"7","author":"IG Schoots","year":"2018","unstructured":"Schoots IG, Osses DF, Drost FH, Verbeek JFM, Remmers S, van Leenders G, et al. Reduction of MRI-targeted biopsies in men with low-risk prostate cancer on active surveillance by stratifying to PI-RADS and PSA-density, with different thresholds for significant disease. Transl Androl Urol. 2018;7(1):132\u201344.","journal-title":"Transl Androl Urol"},{"key":"1719_CR29","doi-asserted-by":"crossref","unstructured":"Schoots IG, Padhani AR. Risk-adapted biopsy decision based on prostate magnetic resonance Imag Ing and prostate-specific antigen density for enhanced biopsy avoidanc e in first prostate cancer diagnostic evaluation. BJU Int.127(2):175\u20138.","DOI":"10.1111\/bju.15277"},{"issue":"3","key":"1719_CR30","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/j.juro.2017.03.130","volume":"198","author":"FA Distler","year":"2017","unstructured":"Distler FA, Radtke JP, Bonekamp D, Kesch C, Schlemmer HP, Wieczorek K, et al. The value of PSA density in combination with PI-RADS\u2122 for the accuracy of prostate Cancer prediction. J Urol. 2017;198(3):575\u201382.","journal-title":"J Urol"}],"container-title":["BMC Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12894-025-01719-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12894-025-01719-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12894-025-01719-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,7]],"date-time":"2025-03-07T06:58:27Z","timestamp":1741330707000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcurol.biomedcentral.com\/articles\/10.1186\/s12894-025-01719-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,3]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1719"],"URL":"https:\/\/doi.org\/10.1186\/s12894-025-01719-5","relation":{},"ISSN":["1471-2490"],"issn-type":[{"value":"1471-2490","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,3]]},"assertion":[{"value":"20 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the institutional ethics committee of Southwest Hospital, Army Medical University (KY2021186) and conducted according to the ethical principles outlined in the Declaration of Helsinki. All patients provided written informed consent. Clinical trial number: not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"42"}}